LEQEMBI IQLIK, a weekly at-home injection for early Alzheimer's, now available in the U.S.

Eisai and Biogen have launched LEQEMBI IQLIK, the first weekly subcutaneous injection for early Alzheimer's disease, now available in the U.S. This treatment offers a convenient alternative to intravenous infusions, allowing patients to initiate and maintain therapy at home. LEQEMBI IQLIK aims to improve patient flexibility and reduce healthcare burdens, with support resources including instructional kits and a companion app. The drug has shown significant slowing of cognitive decline in clinical trials, marking a notable advancement in Alzheimer's care.